Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
March 02 2023 - 4:05PM
Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development, and commercialization of targeted therapies
for women’s cancers, today announced that Sean Bohen, M.D., Ph.D.,
President and Chief Executive Officer, will present at the
Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March
15, 2023, at 2:40 p.m. ET.
A live webcast of the virtual presentation and any accompanying
presentation materials will be available under the News &
Events section of Olema’s investor relations website at
www.olema.com. The webcast will be archived for at least 30
days.
About Olema OncologyOlema Oncology is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of targeted therapies for women’s
cancers. Olema’s lead product candidate, OP-1250, is a proprietary,
orally-available small molecule with dual activity as both a
complete estrogen receptor (ER) antagonist (CERAN) and a selective
ER degrader (SERD). It is currently being evaluated both as a
single agent in an ongoing Phase 2 clinical trial, and in
combination with CDK 4/6 inhibitors (palbociclib and ribociclib)
and a PI3Ka inhibitor (alpelisib), in patients with recurrent,
locally advanced or metastatic ER-positive (ER+), human epidermal
growth factor receptor 2-negative (HER2-) breast cancer. OP-1250
has been granted FDA Fast Track designation for the treatment of
ER+/HER2- metastatic breast cancer that has progressed following
one or more lines of endocrine therapy with at least one line given
in combination with a CDK4/6 inhibitor. Olema is headquartered in
San Francisco and has operations in Cambridge,
Massachusetts.
IR Contact:Courtney Dugan, Vice President, Investor
Relations and Communications ir@olema.com
Media Contact:Ignacio Guerrero-Ros, Ph.D., Russo
Partners646-942-5604ignacio.guerrero-ros@russopartnersllc.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jul 2023 to Jul 2024